XUNFEIHEALTH

Xunfei Healthcare staged a rally-fade pattern today, closing 8.3% lower at HKD 74.05 amid heavy afternoon selling pressure, well below the opening price of HKD 80.75. The stock hit an intraday high of HKD 81.40 in the morning session before sliding to an intraday low of HKD 73.00 in the afternoon. Financially, Q4 2025 revenue grew 27.65% YoY to HKD 342.8 million, while net profit surged 429.8% YoY to HKD 5.17 million, though operating income remained negative at -HKD 7.72 million. The current price sits 38.8% below the 52-week high of HKD 121 and trades below both the 20-day MA (HKD 82.35) and 60-day MA (HKD 77.48), suggesting a weak technical position. However, recent news about a strategic MoU to enter the Indonesian market and a Wind ESG A-rating may support long-term prospects.

Xunfei Healthcare tumbled during the session, closing at HKD 80.75, down 6.27%. The stock fell steadily from a morning high of HKD 87.50 to HKD 82.85 by midday, then continued to slide to an intraday low of HKD 80.30 in the afternoon before finishing near the day's bottom. The decline was mainly driven by market digestion of the news that its stake in Beijing Huiji had dropped to 49% following a HKD 1.5275 million share subscription, while a strategic AI medical MOU with Indonesia's PT DSST Mas Gemilang signaled overseas growth but failed to offset profit-taking pressure. Q4 revenue rose 27.65% YoY to HKD 3.43 billion, net loss narrowed 429.8% to HKD 5.2 million, and EPS turned positive to HKD 0.0428, marking continued fundamental improvement; however, the stock traded below its 20-day MA of HKD 82.89 and remained 33.26% off the 52-week high of HKD 121.00, with YTD gain of only 5.42% indicating lingering weakness.